Klinische Studien
Für Patienten
In unserem Studienzentrum liegt der Schwerpunkt auf Studien der Phase II und III.
- aktuelle klinische Studien zu folgenden Indikationen:
Prostatakarzinom | |
---|---|
A confirmatory, prospective, open-label, single-arm, reader-blinded, multi-centre phase 3 study to assess the diagnostic accuracy of Ferumoxtran-10-enhanced Magnetic Resonance Imaging (MRI) and unenhanced MRI in reference to histopathology in newly-diagnosed prostate cancer (PCA) patients, scheduled for radical prostatectomy (RP) wih extended pelvic lymph node dissection (ePLND) | SPL-01-001 |
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer | PRIMORDIUM |
Clinical study to prove the positive healthcare effect of the Uroletics® app in patients with prostate cancer | EUPROS |
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide with Continued | LIBERTAS |
Urothelkarzinom (Harnblase und oberer Harntrakt) | |
Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD | CLIN2001 UCM301 |
A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in | SunRISe-2 |
Nierenzellkarzinom | |
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy | |
A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma | |
Virtual Interactive 3D Modelling to improve Outcomes in Robotic-Assisted Partial Nephrectomy – A Multicentre, Randomised, Controlled Trial | 3DPN |
weitere Informationen finden Sie unter: ClinicalTrials.gov
Sofern Sie in diesem Zusammenhang Fragen haben oder eventuell an einer der Studien in unserer Klinik teilnehmen möchten, setzen Sie sich bitte mit uns in Verbindung.
Kontakt: